Skip to main content
Erschienen in: Current Geriatrics Reports 3/2013

01.09.2013 | Neurology of Aging (KS Marder, Section Editor)

Primary Central Nervous System Tumors in the Aging Population

verfasst von: Fabio M. Iwamoto

Erschienen in: Current Geriatrics Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The incidence of primary brain tumors peaks in the aging population, and advanced age in often a prognostic factor associated with shorter survival. In the United States, it is estimated that 69,720 individuals will be diagnosed with primary CNS tumors in 2013, of which 24,560 are expected to be malignant and 45,160 non-malignant. Approximately 50 % of primary CNS tumors are expected to occur in individuals who are 65 years or older. Management of elderly patients with primary brain tumors is challenging because there is no accepted standard of care treatment and this population may have multiple comorbidities, decreased tolerance to treatment, and increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients with glioblastoma and meningioma, the most common primary brain tumors in this population. Treatment of elderly patients with primary brain tumors needs to be individualized, and old age alone should not preclude the use of life-prolonging treatments.
Literatur
1.
Zurück zum Zitat Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14 Suppl 5:v1–v49.PubMedCrossRef Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14 Suppl 5:v1–v49.PubMedCrossRef
2.
Zurück zum Zitat Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.PubMedCrossRef Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.PubMedCrossRef
3.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef
4.
Zurück zum Zitat Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef
5.
Zurück zum Zitat Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One. 2013;8(4):e62982.PubMedCrossRef Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One. 2013;8(4):e62982.PubMedCrossRef
6.
Zurück zum Zitat Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010;17(5):510–22.PubMedCrossRef Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010;17(5):510–22.PubMedCrossRef
7.
Zurück zum Zitat Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology. Apr 17 2013. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology. Apr 17 2013.
8.
Zurück zum Zitat Curran Jr WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Ins. 1993;85(9):704–10.CrossRef Curran Jr WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Ins. 1993;85(9):704–10.CrossRef
9.
Zurück zum Zitat • Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595–600. This paper reports a new prognostic scheme for patients with glioblastoma 70 years of age and older.PubMedCrossRef • Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595–600. This paper reports a new prognostic scheme for patients with glioblastoma 70 years of age and older.PubMedCrossRef
10.
Zurück zum Zitat Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5–10.CrossRef Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5–10.CrossRef
11.
Zurück zum Zitat McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.PubMedCrossRef McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.PubMedCrossRef
12.
Zurück zum Zitat Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33(1):17–22.PubMedCrossRef Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33(1):17–22.PubMedCrossRef
13.
Zurück zum Zitat Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43.PubMedCrossRef Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43.PubMedCrossRef
14.
Zurück zum Zitat Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100–7.PubMedCrossRef Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100–7.PubMedCrossRef
15.
Zurück zum Zitat Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.PubMedCrossRef Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.PubMedCrossRef
16.
Zurück zum Zitat Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1583–8.CrossRef Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1583–8.CrossRef
17.
Zurück zum Zitat •• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology. 2012;13(9):916–26. Randomized phase 3 trial comparing 2 different radiation schedules and temozolomide and showing that the 6-week course of radiotherapy, which is considered standard for younger patients, may be associated with lower survival in older patients.PubMedCrossRef •• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology. 2012;13(9):916–26. Randomized phase 3 trial comparing 2 different radiation schedules and temozolomide and showing that the 6-week course of radiotherapy, which is considered standard for younger patients, may be associated with lower survival in older patients.PubMedCrossRef
18.
Zurück zum Zitat DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.PubMedCrossRef DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.PubMedCrossRef
19.
Zurück zum Zitat Nayak L, Iwamoto FM. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10(4):252–8.PubMedCrossRef Nayak L, Iwamoto FM. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10(4):252–8.PubMedCrossRef
20.
Zurück zum Zitat Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997–2007). Cancer. 2009;115(16):3758–66.PubMedCrossRef Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997–2007). Cancer. 2009;115(16):3758–66.PubMedCrossRef
21.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology. 2009;10(5):459–66.PubMedCrossRef Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology. 2009;10(5):459–66.PubMedCrossRef
22.
Zurück zum Zitat Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97(3):657–62.PubMedCrossRef Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97(3):657–62.PubMedCrossRef
23.
Zurück zum Zitat Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.PubMedCrossRef Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.PubMedCrossRef
24.
Zurück zum Zitat Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109(2):391–7.PubMedCrossRef Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109(2):391–7.PubMedCrossRef
25.
Zurück zum Zitat •• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology. 2012;13(7):707–15. Phase III trial showing non-inferiority of temozolomide compared to standard radiotherapy in older patients with malignant astrocytomas.PubMedCrossRef •• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology. 2012;13(7):707–15. Phase III trial showing non-inferiority of temozolomide compared to standard radiotherapy in older patients with malignant astrocytomas.PubMedCrossRef
26.
Zurück zum Zitat Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(5):740–5.CrossRef Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(5):740–5.CrossRef
27.
Zurück zum Zitat Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4733–40.CrossRef Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4733–40.CrossRef
28.
Zurück zum Zitat Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010;12(2):164–72.PubMedCrossRef Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010;12(2):164–72.PubMedCrossRef
29.
Zurück zum Zitat Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22.PubMedCrossRef Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22.PubMedCrossRef
30.
Zurück zum Zitat Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry. 2000;68(1):25–8.PubMedCrossRef Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry. 2000;68(1):25–8.PubMedCrossRef
31.
Zurück zum Zitat Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.PubMed Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.PubMed
32.
Zurück zum Zitat Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.PubMedCrossRef Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.PubMedCrossRef
33.
Zurück zum Zitat Kaley TJ, Wen PY, Schiff D, et al. Phase Ii Trial of Sunitinib (Su011248) for Recurrent Meningioma. Neuro-Oncology. 2010;12:75–6. Kaley TJ, Wen PY, Schiff D, et al. Phase Ii Trial of Sunitinib (Su011248) for Recurrent Meningioma. Neuro-Oncology. 2010;12:75–6.
Metadaten
Titel
Primary Central Nervous System Tumors in the Aging Population
verfasst von
Fabio M. Iwamoto
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 3/2013
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-013-0055-4

Weitere Artikel der Ausgabe 3/2013

Current Geriatrics Reports 3/2013 Zur Ausgabe

Neurology of Aging (KS Marder, Section Editor)

Vascular Dementia

Neurology of Aging (KS Marder, Section Editor)

Update on Dementia with Lewy Bodies

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

Changing Epidemiology and Control of Clostridium difficile in Older Adults

Infectious Diseases in the Elderly (SF Bradley, Section Editor)

Emergence and Control of Antibiotic-resistant Gram-negative Bacilli in Older Adults

Neurology of Aging (KS Marder, Section Editor)

Relationship of Gait and Cognition in the Elderly

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.